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Abstract 
In this study, novel condensed 1,4-dihydropyridines bearing cyclopentanone (1-21) or 
tetrahydrothiophene-1,1-dioxide ring (22-42) with various ester substituents were 
synthesized via modified Hantzsch reaction and their calcium channel modulator activities 
were investigated on isolated rat ileum and rat thoracic aorta. The introduction of 
cyclopentanone ring as fused to the 1,4-dihydropyridine nucleus and methyl, ethyl and allyl 
moieties to the ester group led to more active calcium modulators. 
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1. Introduction 
Calcium ions play a critical role in various biological functions such as muscle contraction, 
release of neurotransmitters and regulation of neuronal excitability [1]. Calcium entry into 
the cytosol is mediated by different types of calcium channel with distinct physiological roles 
[2]. L-type channels are confined to cell bodies and regulate contractions in muscle cells. 
Calcium channel antagonists block Ca2+ influx through L-type calcium channels reversibly 
[3]. 1,4-Dihydropyridines (DHP), of which nifedipine is the prototype, are one of the known 
class of calcium antagonists, which are frequently used for the treatment of cardiovascular 
diseases like angina, hypertension and supraventricular tachycardia [4-6].  
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Figure 1: Nifedipine 
Since the introduction of DHPs into clinical use, many DHP analogs have been synthesized 
in order to elucidate the structure-activity relationships and to enhance calcium-modulating 
effects [7]. It was reported that active derivatives could be obtained by introducing the DHP 
structure into condensed ring systems such as hexahydroquinolines, indenopyridines, 
acridines and furoquinolines [8-11]. C-3 and C-5 substituents modulate activity and tissue 
selectivity and different substituents in these positions alter the activity [12]. Studies of fused 
1,4-DHPs, in which one of the ester groups is immobilized, indicate that at least one ester 
group must be cis to the double bond of DHP for hydrogen bonding to the receptor [13]. As 
the substituent at C-4 position, phenyl is preferred because of animal toxicity observed with 
heteroaromatic rings [14]. Phenyl groups which possess one or more electron-withdrawing 
substituents at ortho- or meta-position are preferable to other groups such as alkyls or phenyl 
groups having a substituent at para-position [15, 16].  
The aim of this work is to evaluate the influence of the cyclopentane or tetrahydrothiophene 
rings, fused to DHP ring and various ester groups in combination with two halogens attached 
to the phenyl ring in the 1,4-DHP nucleus. The compounds were synthesized and tested as 
racemates. The calcium modulator activities of the compounds were assayed on isolated rat 
ileum and rat thoracic aorta. Although compound 37 was synthesized before by Dodd and co-
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workers [17], since there is no data about its calcium channel modulatory activity on ileum 
and aorta, it was also synthesized in this study. 
 
2. Material and Methods 
2.1. Chemistry 
2.1.1. General Methods 
All chemicals used in this study were purchased from Aldrich and Fluka. Melting points 
were determined on Thomas Hoover Capillary Melting Point Apparatus and are uncorrected. 
Infrared spectra were recorded on Perkin Elmer FT-IR Spectrum BX. 1H-NMR, 13C-NMR 
DEPT and COSY spectra were obtained in dimethyl sulphoxide (DMSO) solutions on Varian 
Mercury 400, 400 MHz High Performance Digital FT-NMR Spectrometer. Chemical shifts 
are reported in parts per million (ppm) relative to tetramethylsilane. The X-ray 
crystallographic analysis was carried on Nonius Kappa CCD area-detector diffractometer. 
Mass spectra were obtained on Agilent 5973 Network Mass Selective Detector by electron 
ionization.  Elemental analyses were performed on Leco CHNS-932 Elemental Analyzer. 
Purification by column chromatography was carried on Merck silica gel 60 (0.040-0.063 
mm). 
2.1.2. Synthesis  
The compounds were synthesized according to Scheme 1 and 2.  
The synthesis of tetrahydrothiophene-3-one-1,1-dioxide is reported in Scheme 1. 0,1 mol 
tetrahydrothiophen-3-one, 0,1 mol triethyl orthoformate, 0,13 mmol p-toluensulfonic acid an 
2 mL ethanol was stirred for 20 hours. The mixture was treated with 4 mmol anhydrous 
sodium acetate, 0,00085 mmol sodium tungstate dehydrate and 28 mL water. 28 mL 35 %    
solution of hydrogen peroxide in water was added dropwise while keeping the reaction 
cooled to 30 °C.  After stirring over night at room temperature, the resulting product was 
filtered and washed with water to achieve 3,3-diethoxytetrahydrothiephene-1,1-dione. The 
product was stirred in a mixture of HCl and water at 60 °C for 2 hours. The mixture was 
treated with dichloromethane. The dichloromethane layer was isolated and dried with 
MgSO4, filtered and concentrated. The residue was crystallized from ethanol to provide 
tetrahydrothiophene-3-one-1,1-dioxide [18].  
The compounds 1-42 were prepared (Scheme 2) by heating 1,3-cyclopentanedione or  
tetrahydrothiophene-3-one-1,1-dioxide, aromatic aldehyde, appropriate acetoacetate 
compound and ammonium acetate in methanol, according to Hantzsch reaction.  
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Scheme 2.  
X: CO (Compound 1-21), SO2 (Compound 22-42) 
Ar: 2,3-difluorophenyl, 2-fluoro-3-chlorophenyl, 2,3-dichlorophenyl  
R: -CH3, -C2H5, -CH2CH2OCH3, -CH2-CH=CH2, -CH2CH(CH3)2, -C(CH3)3,  -CH2C6H5        
 
Alkyl 2-methyl-4-(2,3-disubstitutedphenyl)-5-oxo-4,5,6,7-tetrahydro-1H-
cyclopenta[b]pyridine-3-carboxylate (Compound 1-21):  
1,3-Cyclopentanedione (0,001 mol), 2,3-disubstituted benzaldehyde (0,001 mol), alkyl 
acetoacetate (0,001 mol) and ammonium acetate (0,005 mol) were refluxed for 8 h. in 15 mL 
methanol. After the reaction was completed, either the reaction mixture was poored into ice-
water, the obtained precipitate was filtered and crystallized from appropriate solvents or the 
solvent (methanol) was removed via rotary evaporator and the crude product was then 
purified by column chromatography using silica gel as the solid phase and a 7:3 mixture of 
ethyl acetate: methanol as mobile phase.  
 
Alkyl 5-methyl-7-(2,3-disubstitutedphenyl)-2,3,4,7-tetrahydrothieno[3,2-b]pyridine-6-
carboxylate-1,1-dioxide (Compound 22-42):  
Tetrahydrothiophene-3-on-1,1-dioxide (0,001 mol), 2,3-disubstituted benzaldehyde (0,001 
mol), alkyl acetoacetate (0,001 mol) and ammonium acetate (0,005 mol) were refluxed for 8 
h. in 15 mL methanol. The precipitate, which was obtained after cooling the reaction mixture, 
was crystallized from methanol.  
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2.2. Pharmacology 
The calcium antagonistic activities of the compounds were determined by the tests performed 
on isolated rat ileum and rat thoracic aorta. All procedures involving animals and their care 
were conducted in conformity with international laws and policies.  
All data are expressed as mean ± standard error. Statistical comparison between groups was 
performed using general linear models and p values, less than 0,005, were considered to be 
statistically significant.  
 
2.2.1. Studies on isolated rat ileum  
Albino rats of either sex weighing 150-200 g were used in pharmacological studies. The 
animals were supplied from the Laboratory Animal Production Center in the Department of 
Pharmacology, School of Medicine, Osmangazi University, Eskişehir, Turkey. The animals 
used in the test were fasted overnight. After the animals were sacrificed by cervical 
dislocation, the ileum (10-15 cm terminal portion) was immediately removed, discarding the 
5-8 cm segment proximal to the ileocaecal junction. Segments 1.5-2 cm long were mounted 
vertically in a 10 ml organ bath containing Tyrode solution of the following composition 
(mmol/L): NaCl: 136.87, KCl: 2.68, CaCl2: 1.80, MgSO4: 0.81, NaH2PO4: 4.16, NaHCO3: 
11.9, glucose: 5.55. The bath contents were maintained at 37 °C and aerated by 95 % O2 and 
5 % CO2. A tension of 2 g was applied and isometric recording was done by using isometric 
transducer (FDT10-A) May TDA95 Transducer Data Acquisition System (May, Commat, 
Ankara, Turkey). The preparations were allowed to equilibrate for 60 min with regular 
washes every 15 min. In order to check calcium antagonistic effects, contractions were 
induced with barium chloride (4.10-3 mol/L, bath concentration). After washing out, this 
process was repeated until the amplitude of the contraction became constant. Investigations 
of the substances were performed using the single-dose technique. Barium chloride 
contractions were induced after addition of the test substances dissolved in DMSO at 10-5  M 
concentration and 5 min exposure  time. Only one compound was tested in each preparation 
[19].  
2.2.2. Studies on rat thoracic artery  
Rat thoracic artery preparations were also obtained from the same animals, which were used 
for isolated rat ileum experiments. Rings (3 mm) were suspended in organ baths of 10 mL 
capacity which contained Tyrode solution. The bath contents were maintained a 37 °C and 
aerated by 95 % O2 and 5 % CO2. A tension of 2 g was applied. The preparations were 
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allowed to equilibrate for 60 min with regular washes every 15 min. In order to check 
calcium antagonistic effects, contractions were induced with 67 mmol/L potassium chloride. 
After washing out, this process was repeated until the amplitude of the contractions became 
constant. Investigations of the substances were performed using single-dose technique. 
Potassium chloride contractions were induced after addition of the test substance and 10 min 
exposure time. During the administration of the individual substances, the preparation was 
washed until the initial situation had been re-established and the potassium chloride 
contractions were induced. The isometric contractions were recorded by an isometric 
transducer (FDT10-A) May TDA95 Transducer Data Acquisition System [20]. 
 
3. Results 
3.1. Chemistry 
Methyl 2-methyl-4-(2,3-difluorophenyl)-5-oxo-4,5,6,7-tetrahydro-1H-
cyclopenta[b]pyridine-3-carboxylate (Compound 1): Purified via column chromatography. 
Yield: 45%. mp: 223 ºC. IR (ν, cm-1): 3288 (N-H), 1699 (C=O, ester), 1638 (C=O, ketone). 
1H-NMR (δ, DMSO-d6): 2.17-2.56 (4H; m; H-6, H-7), 2.27 (3H; s; 2-CH3), 3.40 (3H; s; 
COOCH3), 4.91 (1H; s; H-4), 6.89-7.15 (3H; m; Ar-H), 9.82 (H; s; N-H). 13C-NMR (δ, 
DMSO-d6): 19.2, 24.2, 31.3, 33.8, 51.2, 102.8, 115.1, 124.7, 125.8, 136.7, 147.2, 148.6, 
150.9, 151.1, 164.7, 167.3, 201.0. MS (m/z): 319 [M]+. Anal. Calcd. for C17H15F2NO3: C, 
63.95; H, 4.73; N, 4.39. Found: C, 63.49; H, 4.61; N, 4.43.   
 
 
Ethyl 2-methyl-4-(2,3-difluorophenyl)-5-oxo-4,5,6,7-tetrahydro-1H-
cyclopenta[b]pyridine-3-carboxylate (Compound 2): Purified via column chromatography. 
Yield: 60%. mp: 211 ºC’dir. IR (ν, cm-1): 3275 (N-H), 1698 (C=O, ester), 1634 (C=O, 
ketone). 1H-NMR (δ, DMSO-d6): 0.99 (3H; t; COOCH2CH3), 2.19-2.57 (4H; m; H-6, H-7), 
2.31 (3H; s; 2-CH3), 3.90 (2H; q; COOCH2CH3), 4.95 (1H; s; H-4), 6.92-7.16 (3H; m; Ar-H), 
9.83 (H; s; N-H). 13C-NMR (δ, DMSO-d6): 13.6, 18.6, 23.7, 30.7, 33.3, 59.0, 102.4, 114.4, 
114.9, 124.2, 125.3, 136.5, 136.6, 146.7, 148.0, 164.2, 166.2, 200.5. MS (m/z): 333 [M]+. 
Anal. Calcd. for C18H17F2NO3: C, 64.86; H, 5.14; N, 4.20. Found: C, 64.67; H, 4.55; N, 4.38.   
 
2-Methoxyethyl 2-methyl-4-(2,3-difluorophenyl)-5-oxo-4,5,6,7-tetrahydro-1H-
cyclopenta[b]pyridine-3-carboxylate (Compound 3): Purified via column chromatography. 
Yield: 46%.  mp: 156 ºC. IR (ν, cm-1): 3268 (N-H), 1680 (C=O, ester), 1642 (C=O, ketone).  
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1H-NMR (δ, DMSO-d6): 2.19-2.57 (4H; m; H-6, H-7), 2.31 (3H, s, 2-CH3), 3.15 (3H; s; 
OCH3), 3.31-3.38 (2H; m; CH2OCH3),  3.90-4.02 (2H; m; CH2CH2OCH3),  4.95 (H; s; 4-H), 
6.92-7.15 (3H; m; Ar-H), 9.85 (H; s; N-H). 13C-NMR (δ, DMSO-d6): 18.7, 23.7, 30.7, 33.3, 
57.8, 62.3, 69.6, 102.1, 114.4, 115.0, 124.1, 125.3, 136.3, 145.7, 148.1, 150.5, 164.1, 166.2, 
200.5. MS (m/z): 363 [M]+. Anal. Calcd. for C19H19F2NO4: C, 62.81; H, 5.27; N, 3.85. Found: 
C, 62.16; H, 4.98; N, 3.98.   
 
Allyl 2-methyl-4-(2,3-difluorophenyl)-5-oxo-4,5,6,7-tetrahydro-1H-
cyclopenta[b]pyridine-3-carboxylate (Compound 4): Crystallized from benzene/petroleum 
ether. Yield: 41%.  mp: 183 ºC. IR (ν, cm-1): 3282 (N-H), 1686 (C=O, ester), 1640 (C=O, 
ketone).  1H-NMR (δ, DMSO-d6): 2.14-2.57 (4H; m; H-6, H-7),  2.23 (3H; s; 2-CH3), 4.37 (H; 
dd; CH2A-CH=CH2), 4.43 (H; dd; CH2B-CH=CH2), 4.97 (H; dd; CH2CH=CH2A), 4.98 (H; s; 
4-H), 5.04 (H; dd; CH2CH=CH2B) 5.66-5.75 (H; m; CH=CH2), 6.93-7.15 (3H; m; Ar-H), 9.86 
(H; s; N-H). 13C-NMR (δ, DMSO-d6): 18.8, 23.7, 30.7, 33.3, 63.7, 102.0, 114.7, 115.0, 116.8, 
124.2, 125.2, 132.7, 136.3, 136.4, 145.4, 147.3, 164.1, 165.9, 200.5. MS (m/z): 345 [M]+. 
Anal. Calcd. for C19H17F2NO3: C, 66.08; H, 4.96; N, 4.06. Found: C, 65.11; H, 4.60; N, 4.09.   
 
Isobutyl 2-methyl-4-(2,3-difluorophenyl)-5-oxo-4,5,6,7-tetrahydro-1H-
cyclopenta[b]pyridine-3-carboxylate (Compound 5): Crystallized from ethyl acetate/n-
hexane. Yield: 52%.  mp: 168 ºC. IR (ν, cm-1): 3314 (N-H), 1690 (C=O, ester), 1646 (C=O, 
ketone). 1H-NMR (δ, DMSO-d6): 0.67 (3H, d, COOCH2CHCH3), 0.73 (3H, d, COO 
CH2CHCH3), 1.67-1.75 (H; m; CH(CH3)2), 2.15-2.55 (4H; m; H-6, H-7), 2.33 (3H, s, 2-CH3), 
3.63 (H; dd; CHACH(CH3)2), 3.71 (H; dd; CHBCH(CH3)2), 4.97 (H; s; 4-H), 6.93-7.17 (3H; 
m; Ar-H), 9.79 (H; s; N-H). 13C-NMR (δ, DMSO-d6): 18.6, 18.8, 19.1, 23.6, 27.1, 30.6, 33.3, 
69.3, 102.1, 114.4, 124.2, 125.1, 136.4, 145.3, 147.2, 148.2, 150.5, 164.0, 166.3, 200.4. MS 
(m/z): 360 [M-1]+. Anal. Calcd. for C20H21F2NO3: C, 66.47; H, 5.86; N, 3.88. Found: C, 
66.24; H, 5.86; N, 3.94.   
 
Tert-butyl 2-methyl-4-(2,3-difluorophenyl)-5-oxo-4,5,6,7-tetrahydro-1H-
cyclopenta[b]pyridine-3-carboxylate (Compound 6): Crystallized from ethyl acetate/n-
hexane. Yield: 48%.  mp: 196 ºC. IR (ν, cm-1): 3302 (N-H), 1696 (C=O, ester), 1632 (C=O, 
ketone).  1H-NMR (δ, DMSO-d6): 1.16 (9H; s; COOC(CH3)3), 2.12-2.52 (4H; m; H-6, H-7), 
2.24 (3H; s; 2-CH3), 4.88 (H; s; 4-H), 6.89-7.34 (3H; m; Ar-H), 9.67 (H; s; N-H). 13C-NMR 
(δ, DMSO-d6): 18.9, 23.9, 24.0, 24.1, 28.0, 31.5, 33.7, 79.4, 104.3, 115.0, 124.6, 125.8, 136.9, 
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145.9, 146.1, 148.6, 150.9, 164.5, 166.2, 200.9. MS (m/z): 360 [M-1]+. Anal. Calcd. for 
C20H21F2NO3: C, 66.47; H, 5.86; N, 3.88. Found: C, 66.40; H, 5.80; N, 3.85.   
 
Benzyl 2-methyl-4-(2,3-difluorophenyl)-5-oxo-4,5,6,7-tetrahydro-1H-
cyclopenta[b]pyridine-3-carboxylate (Compound 7): Crystallized from ethyl acetate/n-
hexane. Yield: 54%. mp: 202 ºC. IR (ν, cm-1): 3260 (N-H), 1695 (C=O, ester), 1630 (C=O, 
ketone).1H-NMR (δ, DMSO-d6): 2.19-2.57 (4H; m; H-6, H-7), 2.33 (3H; s; 2-CH3), 4.93, 5.02 
(1H, AB system, JAB=12.8 Hz, COOCH2C6H5), 4.99 (1H; s; H-4), 6.90-7.27 (8H; m; Ar-H), 
9.77 (H; s; N-H). 13C-NMR (δ, DMSO-d6): 18.8, 23.7, 30.7, 33.3, 64.7, 101.8, 114.5, 115.0, 
124.1, 125.2, 127.4, 127.6, 128.1, 136.2, 145.4, 145.6, 147.5, 147.9, 148.1, 150.5, 164.0, 
166.1, 200.5. MS (m/z): 395 [M]+. Anal. Calcd. for C23H19F2NO3: C, 69.87; H, 4.84; N, 3.54. 
Found: C, 69.25; H, 4.77; N, 3.61.   
 
Methyl 2-methyl-4-(2-fluoro-3-chlorophenyl)-5-oxo-4,5,6,7-tetrahydro-1H-
cyclopenta[b]pyridine-3-carboxylate (Compound 8): Purified via column chromatography. 
Yield: 52%. mp: 245 ºC. IR (ν, cm-1): 3268 (N-H), 1709 (C=O, ester), 1634 (C=O, ketone). 
1H-NMR (δ, DMSO-d6): 2.20-2.59 (4H; m; H-6, H-7), 2.30 (3H; s; 2-CH3), 3.44 (3H; s; 
COOCH3), 4.93 (1H; s; H-4), 7.06-7.34 (3H; m; Ar-H), 9.85 (H; s; N-H). 13C-NMR (δ, 
DMSO-d6): 18.7, 23.7, 31.5, 33.3, 50.6, 102.3, 114.8,  119.2, 124.9, 128.1, 129.2, 135.6, 
146.8, 155.5, 164.3, 166.8, 200.5. MS (m/z): 334 [M-1]+. Anal. Calcd. for C17H15ClFNO3: C, 
60.81; H, 4.50; N, 4.17. Found: C, 60.13; H, 4.66; N, 4.29.   
 
Ethyl 2-methyl-4-(2-fluoro-3-chlorophenyl)-5-oxo-4,5,6,7-tetrahydro-1H-
cyclopenta[b]pyridine-3-carboxylate (Compound 9): Purified via column chromatography. 
Yield: 64%. mp: 239 ºC. IR (ν, cm-1): 3272 (N-H), 1698 (C=O, ester), 1632 (C=O, ketone). 
1H-NMR (δ, DMSO-d6): 0.98 (3H; t; COOCH2CH3), 2.20-2.58 (4H; m; H-6, H-7), 2.30 (3H; 
s; 2-CH3), 3.87 (2H; q; COOCH2CH3), 4.94 (1H; s; H-4), 7.06-7.34 (3H; m; Ar-H), 9.84 (H; 
s; N-H). 13C-NMR (δ, DMSO-d6): 13.6, 18.6, 23.7, 31.2, 33.3, 59.0, 102.4, 114.9, 119.1, 
124.9, 129.2, 135.9, 146.7, 152.9, 155.4, 164.2, 166.2, 200.5. MS (m/z): 349 [M]+. Anal. 
Calcd. for C18H17ClFNO3: C, 61.81; H, 4.90; N, 4.00. Found: C, 61.37; H, 5.10; N, 4.11.   
 
 
2-Methoxyethyl 2-methyl-4-(2-fluoro-3-chlorophenyl)-5-oxo-4,5,6,7-tetrahydro-1H-
cyclopenta[b]pyridine-3-carboxylate (Compound 10): Purified via column 
chromatography. Yield: 51%. mp: 158 ºC. IR (ν, cm-1): 3319 (N-H), 1696 (C=O, ester), 1637 
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(C=O, ketone). 1H-NMR (δ, DMSO-d6): 2.12-2.57 (4H; m; H-6, H-7), 2.31 (3H, s, 2-CH3), 
3.15 (3H; s; OCH3), 3.31-3.42 (2H; m; CH2OCH3),  3.91-4.02 (2H; m; CH2CH2OCH3), 4.95 
(H; s; 4-H), 6.92-7.17 (3H; m; Ar-H), 9.85 (H; s; N-H). 13C-NMR (δ, DMSO-d6): 19.2, 24.2, 
31.9, 36.4, 58.4, 64.8, 70.1, 102.6, 115.4, 125.3, 128.5, 129.7, 131.8, 136.1, 147.7, 153.6, 
156.1,166.7, 200.5. MS (m/z): 379 [M]+. Anal. Calcd. for C19H19ClFNO4: C, 60.08; H, 5.04; 
N, 3.69. Found: C, 59.99; H, 4.99; N, 3.73.   
 
Allyl 2-methyl-4-(2-fluoro-3-chlorophenyl)-5-oxo-4,5,6,7-tetrahydro-1H-
cyclopenta[b]pyridine-3-carboxylate (Compound 11): Purified via column 
chromatography. Yield: 49%. mp: 194 ºC. IR (ν, cm-1): 3265 (N-H), 1740 (C=O, ester), 1712 
(C=O, ketone). 1H-NMR (δ, DMSO-d6): 2.15-2.58 (4H; m; H-6, H-7),  2.32 (3H; s; 2-CH3), 
4.36 (H; dd; CH2A-CH=CH2), 4.25 (H; dd; CH2B-CH=CH2), 4.96 (H; s; 4-H), 4.99 (H; dd; 
CH2CH=CH2A), 5.05 (H; dd; CH2CH=CH2B), 5.65-5.76 (H; m; CH=CH2), 7.06-7.33 (3H; m; 
Ar-H), 9.85 (H; s; N-H). 13C-NMR (δ, DMSO-d6): 18.8, 23.7, 31.3, 33.3, 63.7, 102.1, 117.0, 
119.2, 124.9, 128.0, 129.1, 132.6, 135.7, 147.3, 153.0, 155.4, 164.2, 165.9, 200.5. MS (m/z): 
361 [M]+. Anal. Calcd. for C19H17ClFNO3: C, 63.08; H, 4.74; N, 3.87. Found: C, 62.97; H, 
4.89; N, 3.90.   
 
Isobutyl 2-methyl-4-(2-fluoro-3-chlorophenyl)-5-oxo-4,5,6,7-tetrahydro-1H-
cyclopenta[b]pyridine-3-carboxylate (Compound 12): Purified via column 
chromatography. Yield: 56%.  mp: 163 ºC. IR (ν, cm-1): 3254 (N-H), 1697 (C=O, ester), 1628 
(C=O, ketone). 1H-NMR (δ, DMSO-d6): 0.65 (3H; d; COOCH2CHCH3), 0.72 (3H; d; COO 
CH2CHCH3), 1.66-1.74 (H; m; CH(CH3)2), 2.14-2.57 (4H; m; H-6, H-7), 2.33 (3H; s; 2-CH3), 
3.60 (H; dd; CH2ACH(CH3)2), 3.71 (H; dd; CH2BCH(CH3)2), 4.95 (H; s; 4-H), 7.07-7.33 (3H; 
m; Ar-H), 9.86 (H; s; N-H). 13C-NMR (δ, DMSO-d6): 18.5, 18.6, 18.8, 23.7, 27.1, 31.1, 33.3, 
69.4, 102.1, 115.0, 119.3, 125.0, 129.0, 135.9, 147.3, 152.8, 155.3, 164.1, 166.3, 200.4. MS 
(m/z): 377 [M]+. Anal. Calcd. for C20H21ClFNO3: C, 63.58; H, 5.60; N, 3.71. Found: C, 63.63; 
H, 5.41; N, 3.81.   
 
tert-butyl 2-methyl-4-(2-fluoro-3-chlorophenyl)-5-oxo-4,5,6,7-tetrahydro-1H-cyclopenta 
[b]pyridine-3-carboxylate (Compound 13): Crystallized from ethyl acetate/n-hexane. Yield: 
49%. mp: 207 ºC. IR (ν, cm-1): 3266 (N-H), 1696 (C=O, ester), 1631 (C=O, ketone).  1H-
NMR (δ, DMSO-d6): 1.16 (9H; s; COOC(CH3)3), 2.12-2.52 (4H; m; H-6, H-7), 2.24 (3H; s; 2-
CH3), 4.88 (H; s; 4-H), 7.07-7.32 (3H; m; Ar-H), 9.63 (H; s; N-H). 13C-NMR (δ, DMSO-d6): 
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18.9, 24.1, 24.3, 24.5, 28.0, 32.0, 33.7, 79.4, 104.4, 115.0, 119.5, 125.4, 128.3, 129.7, 136.4, 
146.2, 153.3, 155.8, 166.2, 165.9, 200.7. MS (m/z): 377 [M]+. Anal. Calcd. for 
C20H21ClFNO3: C, 63.58; H, 5.60; N, 3.71. Found: C, 63.27; H, 5.22; N, 3.84.   
 
Benzyl 2-methyl-4-(2-fluoro-3-chlorophenyl)-5-oxo-4,5,6,7-tetrahydro-1H-
cyclopenta[b]pyridine-3-carboxylate (Compound 14): Crystallized from ethyl acetate. 
Yield: 48%. mp: 172 ºC. IR (ν, cm-1): 3261 (N-H), 1699 (C=O, ester), 1633 (C=O, ketone). 
1H-NMR (δ, DMSO-d6): 2.19-2.56 (4H; m; H-6, H-7), 2.32 (3H; s; 2-CH3), 4.89, 4.99 (1H, 
AB system, JAB=13.2 Hz, COOCH2C6H5), 4.95 (1H; s; H-4), 7.00-7.36 (8H; m; Ar-H), 9.88 
(H; s; N-H). 13C-NMR (δ, DMSO-d6): 19.3, 24.2, 31.9, 33.8, 65.3, 102.4, 115.5, 119.8, 125.4, 
127.9, 128.1, 128.5, 128.6, 129.6, 135.9, 136.1, 136.8, 148.1, 153.5, 155.9, 164.7, 166.6, 
200.1. MS (m/z): 411 [M]+. Anal. Calcd. for C23H19ClFNO3: C, 67.07; H, 4.65; N, 3.40. 
Found: C, 66.67; H, 4.67; N, 3.40.   
 
Methyl 2-methyl-4-(2,3-dichlorophenyl)-5-oxo-4,5,6,7-tetrahydro-1H-
cyclopenta[b]pyridine-3-carboxylate (Compound 15): Crystallized from ethyl acetate/n-
hexane. Yield: 62%. mp: 216 ºC. IR (ν, cm-1): 3294 (N-H), 1741 (C=O, ester), 1640 (C=O 
gerilim, ketone). 1H-NMR (δ, DMSO-d6): 2.10-2.57 (4H; m; H-6, H-7), 2.29 (3H; s; 2-CH3), 
3.41 (3H; s; COOCH3), 5.17 (1H; s; H-4), 7.14-7.37 (3H; m; Ar-H), 9.76 (H; s; N-H). 13C-
NMR (δ, DMSO-d6): 19.0, 23.7, 33.2, 36.4, 51.0, 103.1, 115.6, 127.8, 128.3, 129.8, 130.5, 
131.2, 146.5, 147.0, 164.0, 166.8, 200.4. DEPT-135 (δ, DMSO-d6): 19.0 (CH3), 23.7 (CH2), 
33.2 (CH2), 36.4 (CH), 51.0 (CH3), 128.3 (CH), 129.8 (CH), 130.5 (CH). MS (m/z): 351 [M-
1]+. Anal. Calcd. for C17H15Cl2NO3: C, 57.97; H, 4.29; N, 3.98. Found: C, 57.91; H, 4.24; N, 
3.90.   
 
Ethyl 2-methyl-4-(2,3-dichlorophenyl)-5-oxo-4,5,6,7-tetrahydro-1H-
cyclopenta[b]pyridine-3-carboxylate (Compound 16): Crystallized from ethyl acetate. 
Yield: 56%. mp: 206 ºC. IR (ν, cm-1): 3380 (N-H), 1675 (C=O, ester), 1639 (C=O, ketone). 
1H-NMR (δ, DMSO-d6): 0.93 (3H; t; COOCH2CH3), 2.14-2.56 (4H; m; H-6, H-7), 2.29 (3H; 
s; 2-CH3), 3.85 (2H; q; COOCH2CH3), 5.71 (1H; s; H-4), 7.15-7.38 (3H; m; Ar-H), 9.80 (H; 
s; N-H). 13C-NMR (δ, DMSO-d6): 14.2, 19.1, 24.2, 33.7, 36.5, 59.4, 103.8, 116.0, 128.3, 
128.8, 129.8, 130.7, 131.7, 147.0, 147.6, 164.4, 166.8, 200.8. MS (m/z): 366 [M]+. Anal. 
Calcd. for C18H17Cl2NO3: C, 59.03; H, 4.68; N, 3.82. Found: C, 59.87; H, 4.56; N, 3.74.   
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2-Methoxyethyl 2-methyl-4-(2,3-dichlorophenyl)-5-oxo-4,5,6,7-tetrahydro-1H-
cyclopenta[b]pyridine-3-carboxylate (Compound 17): Crystallized from 
benzene/petroleum ether. Yield: 58%. mp: 153 ºC. IR (ν, cm-1): 3263 (N-H), 1676 (C=O 
ester), 1637 (C=O, ketone). 1H-NMR (δ, DMSO-d6): 2.12-2.56 (4H; m; H-6, H-7), 2.30 (3H, 
s, 2-CH3), 3.12 (3H; s; OCH3), 3.26-3.34 (2H; m; CH2OCH3),  3.89-3.98 (2H; m; 
CH2CH2OCH3), 5.16 (H; s; 4-H), 7.15-7.37 (3H; m; Ar-H), 9.90 (H; s; N-H). 13C-NMR (δ, 
DMSO-d6): 18.7, 23.7, 33.3, 36.0, 57.8, 62.2, 69.5, 102.9, 115.5, 127.7, 127.9, 128.2, 129.4, 
130.1, 131.3, 146.8, 147.0, 166.3, 200.3. MS (m/z): 396 [M]+. Anal. Calcd. for 
C19H19Cl2NO4: C, 57.59; H, 4.83; N, 3.53. Found: C, 57.70; H, 4.68; N, 3.43.   
 
Allyl 2-methyl-4-(2,3-dichlorophenyl)-5-oxo-4,5,6,7-tetrahydro-1H-
cyclopenta[b]pyridine-3-carboxylate (Compound 18): Crystallized from ethyl acetate/n-
hexane. Yield: 44%. mp: 192 ºC. IR (ν, cm-1): 3315 (N-H), 1711 (C=O, ester), 1640 (C=O, 
ketone). 1H-NMR (δ, DMSO-d6): 2.10-2.55 (4H; m; H-6, H-7),  2.29 (3H; s; 2-CH3), 4.32 (H; 
dd; CH2A-CH=CH2), 4.39 (H; dd; CH2B-CH=CH2), 4.89 (H; dd; CH2CH=CH2A), 4.98 (H; dd; 
CH2CH=CH2B), 5.17 (H; s; 4-H), 5.60-5.69 (H; m; CH=CH2), 7.14-7.35 (3H; m; Ar-H), 9.78 
(H; s; N-H). 13C-NMR (δ, DMSO-d6): 18.5, 23.7, 33.2, 36.7, 79.1, 104.8, 114.7, 127.6, 127.8, 
128.2, 129.4, 130.3, 131.3, 132.1, 145.0, 146.6, 164.1, 165.9, 200.2. MS (m/z): 377 [M-1]+. 
Anal. Calcd. for C19H17Cl2NO3: C, 60.33; H, 4.53; N, 3.70. Found: C, 60.13; H, 4.38; N, 3.83.   
 
Isobutyl 2-methyl-4-(2,3-dichlorophenyl)-5-oxo-4,5,6,7-tetrahydro-1H-
cyclopenta[b]pyridine-3-carboxylate (Compound 19): Crystallized from ethyl acetate. 
Yield: 63%. mp: 234 ºC. IR (ν, cm-1): 3306 (N-H), 1699 (C=O, ester), 1638 (C=O, ketone). 
1H-NMR (δ, DMSO-d6): 0.58 (3H; d; COOCH2CHCH3), 0.69 (3H; d; COO CH2CHCH3), 
1.68-1.76 (H; m; CH(CH3)2), 2.14-2.55 (4H; m; H-6, H-7), 2.32 (3H; s; 2-CH3), 3.58 (H; dd; 
CH2ACH(CH3)2), 3.70 (H; dd; CH2BCH(CH3)2), 5.17 (H; s; 4-H), 7.16-7.37 (3H; m; Ar-H), 
9.78 (H; s; N-H). 13C-NMR (δ, DMSO-d6): 18.6, 18.8, 20.7, 23.7, 27.0, 33.3, 35.9, 69.3, 
103.1, 115.7, 127.8, 127.9, 129.1, 130.1, 131.4, 147.0, 147.1, 163.9, 166.4, 200.3. MS (m/z): 
393 [M-1]+. Anal. Calcd. for C20H21Cl2NO3: C, 60.92; H, 5.37; N, 3.55. Found: C, 60.94; H, 
5.07; N, 3.69.   
 
Tert-butyl 2-methyl-4-(2,3-dichlorophenyl)-5-oxo-4,5,6,7-tetrahydro-1H-
cyclopenta[b]pyridine-3-carboxylate (Compound 20): Crystallized from ethyl acetate/n-
hexane. Yield: 54%. mp: 193 ºC. IR (ν, cm-1): 3276 (N-H), 1697 (C=O, ester), 1634 (C=O, 
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ketone). 1H-NMR (δ, DMSO-d6): 1.14 (9H; s; COOC(CH3)3), 2.11-2.51 (4H; m; H-6, H-7), 
2.21 (3H; s; 2-CH3), 5.08 (H; s; 4-H), 7.14-7.39 (3H; m; Ar-H), 9.66 (H; s; N-H). 13C-NMR 
(δ, DMSO-d6): 18.7, 23.5, 23.6, 23.7, 33.3, 35.9, 38.8, 63.7, 103.2, 115.6, 127.8, 127.9, 129.3, 
130.2, 131.3, 132.7, 147.0, 163.9, 165.9, 200.4. MS (m/z): 394 [M]+. Anal. Calcd. for 
C20H21Cl2NO3: C, 60.92; H, 5.37; N, 3.55. Found: C, 60.84; H, 5.47; N, 3.59.   
Benzyl 2-methyl-4-(2,3-dichlorophenyl)-5-oxo-4,5,6,7-tetrahydro-1H-
cyclopenta[b]pyridine-3-carboxylate (Compound 21): Crystallized from 
benzene/petroleum ether. Yield: 58%. mp: 129 ºC. IR (ν, cm-1): 3257 (N-H), 1698 (C=O, 
ester), 1632 (C=O, ketone). 1H-NMR (δ, DMSO-d6): 2.11-2.56 (4H; m; H-6, H-7), 2.30 (3H; 
s; 2-CH3), 4.87, 4.99 (1H, AB system, JAB=12.8 Hz, COOCH2C6H5), 5.20 (1H; s; H-4), 6.96-
7.35 (8H; m; Ar-H), 9.79 (H; s; N-H). 13C-NMR (δ, DMSO-d6): 19.3, 24.2, 33.7, 36.4, 65.1, 
103.3, 116.2, 127.9, 128.0, 128.2, 128.4, 128.5, 128.7, 129.8, 130.7, 131.9, 132.8, 136.9, 
147.4, 147.9. 165.4, 166.6, 200.8. MS (m/z): 427 [M-1]+. Anal. Calcd. for C23H19Cl2NO3: C, 
64.50; H, 4.47; N, 3.27. Found: C, 64.96; H, 4.27; N, 3.24.   
 
Methyl 5-methyl-7-(2,3-difluorophenyl)-2,3,4,7-tetrahydrothieno[3,2-b]pyridine-6-
carboxylate-1,1-dioxide (Compound 22): Yield: 61%. mp: 264 ºC. IR (ν, cm-1): 3337 (N-
H), 1683 (C=O), 1303, 1166 (S=O). 1H-NMR (δ, DMSO-d6): 2.28 (3H; s; 5-CH3), 2.78 (H; 
ddd; H-3A), 2.85 (H; ddd; H-3B), 3.26 (H; ddd; H-2A), 3.31 (H; ddd; H-2B), 3.44 (3H; s; 
COOCH3), 5.14 (1H; s; H-7), 6.69-7.22 (3H; m; Ar-H), 9.50 (H; s; N-H). 13C-NMR (δ, 
DMSO-d6): 19.2, 23.2, 30.2, 49.2, 51.3, 99.7, 112.0, 115.7, 124.9, 125.4, 135.8, 142.7, 145.9, 
148.3, 151.1, 167.0. MS (m/z): 354 [M-1]+. Anal. Calcd. for C16H15F2NO4S: C, 54.08; H, 
4.25; N, 3.94; S, 9.02. Found: C, 53.89; H, 4.26; N, 4.43; S, 9.18.   
Ethyl 5-methyl-7-(2,3-difluorophenyl)-2,3,4,7-tetrahydrothieno[3,2-b]pyridine-6-
carboxylate-1,1-dioxide (Compound 23): Yield: 75%. mp: 273 ºC. IR (ν, cm-1): 3333 (N-
H), 1686 (C=O), 1252, 1135 (S=O). 1H-NMR (δ, DMSO-d6): 0.99 (3H; t; COOCH2CH3), 
2.28 (3H; s; 5-CH3), 2.77 (H; ddd; H-3A), 2.84 (H; ddd; H-3B), 3.26 (H; ddd; H-2A), 3.32 (H; 
ddd; H-2B), 3.85 (H; dq; COOCH2A-CH3), 3.92 (H; dq; COOCH2B-CH3) 5.15 (H; s; H-7), 
6.97-7.22 (3H; m; Ar-H), 9.48 (H; s; N-H). 13C-NMR (δ, DMSO-d6): 14.2, 19.1, 23.2, 30.1, 
49.1, 59.6, 99.9, 112.0, 115.6, 115.8, 125.0, 125.5, 135.9, 136.1, 142.6, 148.2, 166.4. MS 
(m/z): 368 [M-1]+. Anal. Calcd. for C17H17F2NO4S : C, 55.28; H, 4.64; N, 3.79; S, 8.68. 
Found: C, 54.96; H, 4.26; N, 3.94; S, 8.65.   
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2-Methoxyethyl 5-methyl-7-(2,3-difluorophenyl)-2,3,4,7-tetrahydrothieno[3,2-
b]pyridine-6-carboxylate-1,1-dioxide (Compound 24): Yield: 57. mp: 239 ºC’dir. IR (ν, 
cm-1): 3343 (N-H), 1665 (C=O), 1279, 1096 (S=O). 1H-NMR (δ, DMSO-d6): 2.11 (H; ddd; 
H-3A), 2.28 (3H; s; 5-CH3), 2.43 (H; ddd; H-3B), 3.02 (3H; s; OCH3), 3.08 (H; ddd; H-2A), 
3.21-3.35 (2H; m; CH2OCH3), 3.39 (H; ddd; H-2B), 3.78 (H; ddd; CH2ACH2OCH3), 3.93 (H; 
ddd; CH2BCH2OCH3), 4.59 (H; s; 7-H), 5.89 (H; s; N-H), 6.96-7.44 (3H; m; Ar-H). 13C-
NMR (δ, DMSO-d6): 20.2, 33.8, 34.2, 48.6, 57.8, 65.9, 70.0, 82.5, 99.3, 111.7, 115.9, 123.8, 
126.8, 133.0, 142.1, 148.4, 153.6, 166.4. MS (m/z): 398 [M-1]+. Anal. Calcd. for 
C18H19F2NO5S: C, 54.13; H, 4.79; N, 3.51; S, 8.03. Found: C, 54.40; H, 4.55; N, 3.55; S, 
7.89.   
 
Allyl 5-methyl-7-(2,3-difluorophenyl)-2,3,4,7-tetrahydrothieno[3,2-b]pyridine-6-
carboxylate-1,1-dioxide (Compound 25): Yield: 64%. mp: 240 ºC. IR (ν, cm-1): 3339 (N-
H), 1666 (C=O), gerilim), 1288, 1132 (S=O). 1H-NMR (δ, DMSO-d6): 2.12 (H; ddd; H-3A), 
2.29 (3H; s; 5-CH3), 2.40 (H; ddd; H-3B), 3.08 (H; ddd; H-2A), 3.40 (H; ddd; H-2B), 4.37 (H; 
dd; CH2ACH=CH2), 4.42 (H; dd; CH2BCH=CH2), 4.94 (H; dd; CH2CH=CH2A), 5.02 (H; dd; 
CH2CH=CH2B), 5.18 (H; s; 7-H), 5.66-5.73 (H; m; CH=CH2), 6.69-7.49 (3H; m; Ar-H),  9.53 
(H; s; N-H). 13C-NMR (δ, DMSO-d6): 20.8, 30.1, 34.3, 49.2, 64.3, 83.0, 99.8, 115.7, 117.3, 
124.2, 125.4, 127.3, 129.6, 135.8, 142.5, 148.6, 150.2, 166.0. MS (m/z): 381 [M]+. Anal. 
Calcd. for C18H17F2NO4S: C, 56.69; H, 4.49; N, 3.67; S, 8.41. Found: C, 57.08; H, 4.45; N, 
3.72; S, 8.45.   
Isobutyl 5-methyl-7-(2,3-difluorophenyl)-2,3,4,7-tetrahydrothieno[3,2-b]pyridine-6-
carboxylate-1,1-dioxide (Compound 26): Yield: 68%. mp: 264 ºC. IR (ν, cm-1): 3364 (N-
H), 1683 (C=O), 1245, 1084 (S=O). 1H-NMR (δ, DMSO-d6): 0.55 (3H; d; COOCHCH3), 
0.58 (3H; d; COOCHCH3), 1.48-1.57 (H; m; CH(CH3)2), 2.13 (H; ddd; H-3A), 2.32 (3H; s; 5-
CH3), 2.46 (H; ddd; H-3B), 3.03 (H; ddd; H-2A), 3.37 (H; ddd; H-2B), 3.49 (H; dd; 
CH2ACH(CH3)2), 3.65 (H; dd; CH2BCH(CH3)2), 4.62 (H; s; 7-H), 5.88 (H; s; N-H), 7.01-7.45 
(3H; m; Ar-H). 13C-NMR (δ, DMSO-d6): 18.9, 19.0, 20.7, 27.6, 34.3, 34.7, 49.2, 69.9, 83.0, 
99.9, 115.7, 124.0, 125.2, 127.3, 133.6, 142.5, 148.8, 154.1, 166.8. MS (m/z): 397 [M]+. 
Anal. Calcd. for C19H21F2NO4S: C, 57.42; H, 5.33; N, 3.52; S, 8.07. Found: C, 57.06; H, 
4.94; N, 3.57; S, 8.34.   
Tert-butyl 5-methyl-7-(2,3-difluorophenyl)-2,3,4,7-tetrahydrothieno[3,2-b]pyridine-6-
carboxylate-1,1-dioxide (Compound 27): Yield: 58%. mp: 259 ºC. IR (ν, cm-1): 3368 (N-
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H), 1684 (C=O), 1304, 1133 (S=O). 1H-NMR (δ, DMSO-d6): 1.09 (9H; s; COOC(CH3)3), 
2.12 (H; ddd; H-3A), 2.26 (3H; s; 5-CH3), 2.44 (H; ddd; H-3B), 3.06 (H; ddd; H-2A), 3.39 (H; 
ddd; H-2B), 4.53 (H; s; 7-H), 5.89 (H; s; N-H), 6.99-7.27 (3H; m; Ar-H). 13C-NMR (δ, 
DMSO-d6): 20.5, 28.2, 28.4, 28.7, 30.3, 34.5, 49.1, 80.9, 92.6, 101.2, 115.6, 124.9, 126.0, 
134.3, 136.1, 142.4, 147.3, 153.0, 166.5. MS (m/z): 397 [M]+. Anal. Calcd. for 
C19H21F2NO4S: C, 57.42; H, 5.33; N, 3.52; S, 8.07. Found: C, 57.16; H, 5.28; N, 3.77; S, 
8.63.   
 
Benzyl 5-methyl-7-(2,3-difluorophenyl)-2,3,4,7-tetrahydrothieno[3,2-b]pyridine-6-
carboxylate-1,1-dioxide (Compound 28): Yield: 67%. mp: 237 ºC’dir. IR (ν, cm-1): 3341 
(N-H), aromatik), 1665 (C=O), 1288, 1131 (S=O). 1H-NMR (δ, DMSO-d6): 2.14 (H; ddd; H-
3A), 2.33 (3H; s; 5-CH3), 2.46 (H; ddd; H-3B), 3.05 (H; ddd; H-2A), 3.39 (H; ddd; H-2B), 4.65 
(H; s; 7-H), 4.77, 4.98 (1H, AB system, JAB=13.2 Hz, COOCH2C6H5), 5.94 (H; s; N-H) 6.81-
7.55 (8H; m; Ar-H). 13C-NMR (δ, DMSO-d6): 20.8, 28.6, 34.7, 51.0, 66.4, 81.2, 90.1, 115.3, 
115.5, 124.1, 125.8, 127.2, 127.7, 128.4, 128.6, 133.5, 133.6, 137.4, 143.6, 149.9, 154.6, 
166.6. MS (m/z): 430 [M-1]+. Anal. Calcd. for C22H19F2NO4S: C, 61.24; H, 4.44; N, 3.25; S, 
7.43. Found: C, 61.52; H, 4.56; N, 3.29; S, 7.31.   
 
 
Methyl 5-methyl-7-(2-fluoro-3-chlorophenyl)-2,3,4,7-tetrahydrothieno[3,2-b]pyridine-
6-carboxylate-1,1-dioxide (Compound 29): Yield: 59%. mp:245 ºC. IR (ν, cm-1): 3346 (N-
H), 1663 (C=O), 1303, 1128 (S=O). 1H-NMR (δ, DMSO-d6): 2.27 (3H; s; 5-CH3), 2.78 (H; 
ddd; H-3A), 2.85 (H; ddd; H-3B), 3.25 (H; ddd; H-2A), 3.33 (H; ddd; H-2B), 3.43 (3H; s; 
COOCH3), 5.13 (1H; s; H-7), 7.08-7.37 (3H; m; Ar-H), 9.51 (H; s; N-H). 13C-NMR (δ, 
DMSO-d6): 19.2, 23.2, 30.9, 49.2, 51.3, 99.7, 112.0, 119.7, 125.6, 129.2, 134.9, 135.1, 142.7, 
148.3, 156.0, 167.0. EI-MS (m/z): 370 [M-1]+. Anal. Calcd. for C16H15ClFNO4S: C, 51.69; 
H, 4.07; N, 3.77; S, 8.62. Found: C, 51.91; H, 3.74; N, 3.89; S, 8.45.   
 
Ethyl 5-methyl-7-(2-fluoro-3-chlorophenyl)-2,3,4,7-tetrahydrothieno[3,2-b]pyridine-6-
carboxylate-1,1-dioxide (Compound 30): Yield: 56%. mp: 239 ºC. IR (ν, cm-1): 3348 (N-
H), 1663 (C=O), 1287, 1127 (S=O). 1H-NMR (δ, DMSO-d6): 0.97 (3H; t; COOCH2CH3), 
2.12 (H; ddd; H-3A), 2.28 (3H; s; 5-CH3), 2.45 (H; ddd; H-3B), 3.03 (H; ddd; H-2A), 3.37 (H; 
ddd; H-2B), 3.74 (H; dq; COOCH2A-CH3), 3.87 (H; dq; COOCH2B-CH3) 5.12 (H; s; H-7), 
7.04-7.43 (3H; m; Ar-H), 9.51 (H; s; N-H). 13C-NMR (δ, DMSO-d6): 14.1, 20.7, 30.6, 34.6, 
51.0, 59.6, 81.1, 90.8, 112.0, 129.4, 133.1, 135.4, 142.6, 148.2, 154.0, 156.5, 166.9. EI-MS 
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(m/z): 385 [M]+. Anal. Calcd. for C17H17ClFNO4S : C, 52.92; H, 4.44; N, 3.63; S, 8.31. 
Found: C, 52.22; H, 4.61; N, 3.81; S, 8.42.   
 
2-Methoxythyl 5-methyl-7-(2-fluoro-3-chlorophenyl)-2,3,4,7-tetrahydrothieno[3,2-
b]pyridine-6-carboxylate-1,1-dioxide (Compound 31): Yield: 64%. mp: 189 ºC. IR (ν, cm-
1): 3332 (N-H), 1665 (C=O), 1284, 1125 (S=O gerilim). 1H-NMR (δ, DMSO-d6): 2.12 (H; 
ddd; H-3A), 2.28 (3H; s; 5-CH3), 2.42 (H; ddd; H-3B), 3.01 (3H; s; OCH3), 3.08 (H; ddd; H-
2A), 3.21-3.27 (2H; m; CH2OCH3), 3.38 (H; ddd; H-2B), 3.78 (H; ddd; CH2ACH2OCH3), 3.93 
(H; ddd; CH2BCH2OCH3), 4.57 (H; s; 7-H), 5.88 (H; s; N-H), 7.02-7.38 (3H; m; Ar-H). 13C-
NMR (δ, DMSO-d6): 20.7, 29.0, 34.6, 51.2, 58.3, 66.3, 70.5, 81.1, 90.5, 119.5, 124.7, 128.6, 
129.5, 129.8, 133.0, 150.3, 154.2,166.9. EI-MS (m/z): 415 [M]+. Anal. Calcd. for 
C18H19ClFNO5S: C, 51.99; H, 4.61; N, 3.37; S, 7.71. Found: C, 51.10; H, 4.54; N, 3.49; S, 
7.89.   
     
Allyl 5-methyl-7-(2-fluoro-3-chlorophenyl)-2,3,4,7-tetrahydrothieno[3,2-b]pyridine-6-
carboxylate-1,1-dioxide (Compound 32): Yield: 58%. mp: 232ºC’dir. IR (ν, cm-1): 3335 
(N-H), 1699 (C=O), 1281, 1129 (S=O). 1H-NMR (δ, DMSO-d6): 2.13 (H; ddd; H-3A), 2.34 
(3H; s; 5-CH3), 2.44 (H; ddd; H-3B), 3.03 (H; ddd; H-2A), 3.39 (H; ddd; H-2B), 4.27 (H; dd; 
CH2ACH=CH2), 4.35 (H; dd; CH2BCH=CH2), 4.75 (H; s; 7-H), 4.84 (H; dd; CH2CH=CH2A), 
4.93 (H; dd; CH2CH=CH2B) 5.57-5.65 (H; m; CH=CH2), 5.86 (H; s; N-H) 7.22-7.57 (3H; m; 
Ar-H). 13C-NMR (δ, DMSO-d6): 20.8, 30.6, 34.2, 51.0, 66.3, 83.0, 99.6, 119.6, 124.8, 125.6, 
128.7, 129.3, 132.7, 133.8, 148.8, 150.3, 154.5, 166.5. EI-MS (m/z): 397 [M]+. Anal. Calcd. 
for C18H17ClFNO4S : C, 54.34; H, 4.31; N, 3.52; S, 8.06. Found: C, 54.03; H, 4.53; N, 3.71; 
S, 8.55.   
 
Isobutyl 5-methyl-7-(2-fluoro-3-chlorophenyl)-2,3,4,7-tetrahydrothieno[3,2-b]pyridine-
6-carboxylate-1,1-dioxide (Compound 33): Yield: 66%. mp: 243 ºC’dir. IR (ν, cm-1): 3339 
(N-H), 1683 (C=O), 1304, 1132 (S=O).  1H-NMR (δ, DMSO-d6): 0.52 (3H; d; COOCHCH3), 
0.56 (3H; d; COOCHCH3), 1.48-1.55 (H; m; CH(CH3)2), 2.11 (H; ddd; H-3A), 2.31 (3H; s; 5-
CH3), 2.44 (H; ddd; H-3B), 3.02 (H; ddd; H-2A), 3.38 (H; ddd; H-2B), 3.47 (H; dd; 
CH2ACH(CH3)2), 3.62 (H; dd; CH2BCH(CH3)2), 4.58 (H; s; 7-H), 5.86 (H; s; N-H), 7.05-7.44 
(3H; m; Ar-H). 13C-NMR (δ, DMSO-d6): 18.9, 19.0, 20.7, 27.7, 34.2, 34.7, 49.2, 69.9, 83.0, 
90.2, 112.2, 124.8, 125.7, 128.6, 129.5, 131.1, 142.5, 156.5, 166.8. MS (m/z): 413 [M]+. 
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Anal. Calcd. for C19H21ClFNO4S : C, 55.14; H, 5.11; N, 3.38; S, 7.75. Found: C, 55.38; H, 
4.51; N, 3.57; S, 7.27.   
 
Tert-butyl 5-methyl-7-(2-fluoro-3-chlorophenyl)-2,3,4,7-tetrahydrothieno[3,2-
b]pyridine-6-carboxylate-1,1-dioxide (Compound 34): Yield: 70%. mp: 241 ºC’dir. IR (ν, 
cm-1): 3340 (N-H), 1689 (C=O), 1304, 1132 (S=O). 1H-NMR (δ, DMSO-d6): 1.05 (9H; s; 
COOC(CH3)3), 2.10 (H; ddd; H-3A), 2.23 (3H; s; 5-CH3), 2.42 (H; ddd; H-3B), 3.06 (H; ddd; 
H-2A), 3.38 (H; ddd; H-2B), 4.49 (H; s; 7-H), 5.86 (H; s; N-H), 7.05-7.40 (3H; m; Ar-H). 13C-
NMR (δ, DMSO-d6): 20.0, 27.5, 27.6, 27.7, 30.3, 34.0, 48.5, 80.4, 92.1, 99.1, 124.4, 125.2, 
128.4, 129.2, 130.6, 133.3, 149.8, 156.0, 166.0. MS (m/z): 413 [M]+. Anal. Calcd. for 
C19H21ClFNO4S : C, 55.14; H, 5.11; N, 3.38; S, 7.75. Found: C, 55.17; H, 4.95; N, 3.61; S, 
7.05.   
 
Benzyl 5-methyl-7-(2-fluoro-3-chlorophenyl)-2,3,4,7-tetrahydrothieno[3,2-b]pyridine-6-
carboxylate-1,1-dioxide (Compound 35): Yield: 72%. mp: 208ºC. IR (ν, cm-1): 3348 (N-
H), 1664 (C=O), 1303, 1130 (S=O). 1H-NMR (δ, DMSO-d6): 2.12 (H; ddd; H-3A), 2.33 (3H; 
s; 5-CH3), 2.43 (H; ddd; H-3B), 3.04 (H; ddd; H-2A), 3.38 (H; ddd; H-2B), 4.61 (H; s; 7-H), 
4.74, 4,94 (1H, AB system, JAB=13.2 Hz, COOCH2C6H5), 5.90 (H; s; N-H), 6.77-7.54 (8H; 
m; Ar-H). 13C-NMR (δ, DMSO-d6): 20.8, 29.0, 34.7, 49.2, 66.8, 83.0, 89.9, 124.9, 125.6, 
127.7, 128.1, 128.6, 129.1, 129.6, 131.1, 132.8, 133.0, 136.7, 137.4, 142.5, 156.5, 166.6. EI-
MS (m/z): 447 [M]+. Anal. Calcd. for C22H19ClFNO4S : C, 58.99; H, 4.28; N, 3.13; S, 7.16. 
Found: C, 58.12; H, 4.43; N, 3.34; S, 7.73.   
Methyl 5-methyl-7-(2,3-dichlorophenyl)-2,3,4,7-tetrahydrothieno[3,2-b]pyridine-6-
carboxylate-1,1-dioxide (Compound 36): Yield: 48%. mp: 230 ºC. IR (ν, cm-1): 3373 (N-
H), 1660 (C=O), 1299, 1127 (S=O). 1H-NMR (δ, DMSO-d6): 2.11 (H, ddd, H-3A), 2.32 (3H; 
s; 5-CH3), 2.42 (H, ddd, H-3B), 3.01 (H, ddd, H-2A), 3.34 (3H; s; COOCH3), 3.40 (H, ddd, H-
2B), 4.69 (1H; s; H-7), 5.82 (H; s; N-H), 7.18-7.46(3H; m; Ar-H). 13C-NMR (δ, DMSO-d6): 
20.8, 34.2, 34.8, 50.7, 51.1, 81.5, 91.2, 127.7, 128.8, 129.4, 129.8, 130.5, 131.8, 143.2, 153.9, 
167.6. DEPT-135 (δ, DMSO-d6): 20.8 (CH3), 34.2 (CH), 34.8 (CH2), 50.7 (CH2), 51.1 (CH3),  
127.7 (CH), 128.8 (CH),129.4 (CH). EI-MS (m/z): 388 [M]+. Anal. Calcd. for 
C16H15Cl2NO4S: C, 49.50; H, 3.89; N, 3.61; S, 8.26. Found: C, 49.10; H, 4.15; N, 3.62; S, 
8.01.   
Ethyl 5-methyl-7-(2,3-dichlorophenyl)-2,3,4,7-tetrahydrothieno[3,2-b]pyridine-6-
carboxylate-1,1-dioxide (Compound 37): Yield: 53%. mp: 228 ºC. IR (ν, cm-1): 3369 (N-
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H), 1660 (C=O), 1299, 1093 (S=O). 1H-NMR (δ, DMSO-d6): 0.81 (3H; t; COOCH2CH3), 
2.12 (H; ddd; H-3A), 2.31 (3H; s; 5-CH3), 2.44 (H; ddd; H-3B), 3.03 (H; ddd; H-2A), 3.36 (H; 
ddd; H-2B), 3.71 (H; dq; COOCH2A-CH3), 3.82 (H; dq; COOCH2B-CH3) 4.72 (H; s; H-7), 
5.86 (H; s; N-H), 7.22-7.47 (3H; m; Ar-H). 13C-NMR (δ, DMSO-d6): 14.3, 20.6, 30.5, 34.3, 
51.1, 58.5, 81.3, 91.8, 127.6, 128.6, 129.5, 130.5, 131.6, 131.9, 143.7, 153.7, 167.0. EI-MS 
(m/z): 401 [M-1]+. Anal. Calcd. for C17H17Cl2NO4S: C, 50.76; H, 4.26; N, 3.48; S, 7.97. 
Found: C, 50.98; H, 4.22; N, 3.53; S, 8.03.    
2-Methoxythyl 5-methyl-7-(2,3-dichlorophenyl)-2,3,4,7-tetrahydrothieno[3,2-
b]pyridine-6-carboxylate-1,1-dioxide (Compound 38): Yield: 41%.   mp: 196 ºC. IR (ν, 
cm-1): 3345 (N-H), 1663 (C=O), 1355, 1129 (S=O). 1H-NMR (δ, DMSO-d6): 2.12 (H, ddd, 
H-3A), 2.32 (3H, s, 5-CH3), 2.44 (H, ddd, H-3B), 3.02 (3H; s; OCH3), 3.08 (H, ddd, H-2A), 
3.21-3.29 (2H; m; CH2OCH3), 3.40 (H, ddd, H-2B), 3.78 (H; ddd; CH2ACH2OCH3), 3.92 (H; 
ddd; CH2BCH2OCH3), 4.73 (H; s; 7-H), 5.86 (H; s; N-H), 7.20-7.48 (3H; m; Ar-H). 13C-
NMR (δ, DMSO-d6): 20.6, 34.3, 34.7, 48.9, 58.3, 65.6, 70.5, 91.4, 100.1, 127.5, 128.6, 129.8, 
130.5, 131.6, 139.3, 143.5, 154.1, 166.9. EI-MS (m/z): 432 [M]+. Anal. Calcd. for 
C18H19Cl2NO5S: C, 50.01; H, 4.43; N, 3.24; S, 7.42. Found: C, 50.22; H, 4.50; N, 3.31; S, 
7.92.   
     
Allyl 5-methyl-7-(2,3-dichlorophenyl)-2,3,4,7-tetrahydrothieno[3,2-b]pyridine-6-
carboxylate-1,1-dioxide (Compound 39): Yield: 47%.  mp: 188 ºC. IR (ν, cm-1): 3342 (N-
H), 1664 (C=O), 1303, 1129 (S=O). 1H-NMR (δ, DMSO-d6): 2.13 (H; ddd; H-3A), 2.34 (3H; 
s; 5-CH3), 2.44 (H; ddd; H-3B), 3.03 (H; ddd; H-2A), 3.39 (H; ddd; H-2B), 4.27 (H; dd; 
CH2ACH=CH2), 4.35 (H; dd; CH2BCH=CH2), 4.75 (H; s; 7-H), 4.84 (H; dd; CH2CH=CH2A), 
4.93 (H; dd; CH2CH=CH2B) 5.57-5.65 (H; m; CH=CH2), 5.86 (H; s; N-H), 7.22-7.57 (3H; m; 
Ar-H). 13C-NMR (δ, DMSO-d6): 20.8, 30.5, 34.1, 51.0, 65.5, 91.0, 100.1, 115.7, 127.6, 
128.8, 129.8, 130.5, 131.7, 133.7, 139.3, 150.4, 154.4, 166.5. EI-MS (m/z): 413 [M-1]+. 
Anal. Calcd. for C18H17Cl2NO4S : C, 52.18; H, 4.14; N, 3.38; S, 7.74. Found: C, 52.29; H, 
4.26; N, 3.43; S, 7.72.   
 
Isobutyl 5-methyl-7-(2,3-dichlorophenyl)-2,3,4,7-tetrahydrothieno[3,2-b]pyridine-6-
carboxylate-1,1-dioxide (Compound 40):  Yield: 58%. mp: 244 ºC. IR (ν, cm-1): 3345 (N-
H), 1663 (C=O), 1302, 1128 (S=O). 1H-NMR (δ, DMSO-d6): 0.52 (3H; d; COOCHCH3), 
0.56 (3H; d; COOCHCH3), 1.47-1.54 (H; m; CH(CH3)2), 2.12 (H; ddd; H-3A), 2.30 (3H; s; 5-
CH3), 2.44 (H; ddd; H-3B), 3.04 (H; ddd; H-2A), 3.39 (H; ddd; H-2B), 3.48 (H; dd; 
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CH2ACH(CH3)2), 3.61 (H; dd; CH2BCH(CH3)2), 4.73 (H; s; 7-H), 5.84 (H; s; N-H), 7.22-7.47 
(3H; m; Ar-H). 13C-NMR (δ, DMSO-d6): 18.9, 19.0, 20.6, 27.7, 34.1, 34.8, 51.1, 68.9, 81.3, 
91.1, 127.6, 128.7, 129.5, 130.5, 131.8, 133.2, 143.5, 154.1, 166.9. EI-MS (m/z): 429 [M-1]+. 
Anal. Calcd. for C19H21Cl2NO4S : C, 53.03; H, 4.92; N, 3.25; S, 7.45. Found: C, 53.19; H, 
4.89; N, 3.35; S, 7.79.   
 
Tert-butyl 5-methyl--(2,3-dichlorophenyl)-2,3,4,7-tetrahydrothieno[3,2-b]pyridine-6-
carboxylate-1,1-dioxide (Compound 41):  Yield: 58%. mp: 248 ºC. IR (ν, cm-1): 3344 (N-
H), 1689 (C=O), 1364, 1156 (S=O). 1H-NMR (δ, DMSO-d6): 1.06 (9H; s; COOC(CH3)3), 
2.11 (H; ddd; H-3A), 2.28 (3H; s; 5-CH3), 2.44 (H; ddd; H-3B), 3.06 (H; ddd; H-2A), 3.37 (H; 
ddd; H-2B), 4.65 (H; s; 7-H), 5.75 (H; s; N-H), 7.19-7.47 (3H; m; Ar-H). 13C-NMR (δ, 
DMSO-d6): 19.8, 27.5, 27.6, 27.7, 30.0, 34.1, 48.5, 80.6, 92.9, 101.9, 121.1, 128.0, 129.1, 
130.8, 131.2, 131.4, 143.8, 152.6,166.1. EI-MS (m/z): 429 [M-1]+. Anal. Calcd. for 
C19H21Cl2NO4S : C, 53.03; H, 4.92; N, 3.25; S, 7.45. Found: C, 53.38; H, 4.74; N, 3.35; S, 
7.79.   
Benzyl 5-methyl-7-(2,3-dichlorophenyl)-2,3,4,7-tetrahydrothieno[3,2-b]pyridine-6-
carboxylate-1,1-dioxide (Compound 42):  Yield: 55%. mp: 214 ºC. IR (ν, cm-1): 3359 (N-
H), 1661 (C=O), 1300, 1178 (S=O). 1H-NMR (δ, DMSO-d6): 2.13 (H; ddd; H-3A), 2.35 (3H; 
s; 5-CH3), 2.44 (H; ddd; H-3B), 3.04 (H,; ddd; H-2A), 3.39 (H; ddd; H-2B), 4.73, 4,94 (1H, 
AB system, JAB=12.8 Hz, COOCH2C6H5), 4.75 (H; s; 7-H), 5.88 (H; s; N-H), 6.77-7.56 (8H; 
m; Ar-H). 13C-NMR (δ, DMSO-d6): 20.7, 34.1, 34.7, 51.1, 64.3, 81.3, 90.9, 127.0, 127.7, 
128.4, 128.8, 129.5, 129.9, 130.6, 130.8, 131.2, 131.9, 132.3, 137.3, 143.4, 154.7, 166.6. EI-
MS (m/z): 464 [M]+. Anal. Calcd. for C22H19Cl2NO4S : C, 56.90; H, 4.12; N, 3.02; S, 6.90. 
Found: C, 56.06; H, 4.43; N, 3.10; S, 6.95.   
 
3.2. Pharmacology 
Relexant effects of the compounds and nicardipine on isolated rat ileum, on rat thoracic 
artery and half maximal effective concentration (EC50) of the selected compounds are given 
in Table 1 and Table 2, respectively. 
 
    
 
 
 
 
 
 20 
  Table 1. Relexant effects of the synthesized compounds and nicardipine (10-5 mol/L). 
 
Compound Inhibition % a Inhibition % b Compound Inhibition % a Inhibition 
% b 
1 89.00 ± 13.05 4.18 ±1.53* 22 78.67 ± 23.14 3.08 ±1.74* 
2 93.50 ± 8.67 3.77 ±0.99* 23 88.00 ± 15.60 2.80 ± 1.82* 
3 47.00 ± 23.07 * - 24 0 - 
4 58.50 ±14.27* 3.42 ± 1.31* 25 80.12 ±9.55 7.68 ±2.38 
5 48.83 ± 8.04 * - 26 47.40 ± 16.00* - 
6 27.50 ±10.75* - 27 45.60±14.66 * - 
7 99.17 ± 2.04 2.15 ± 1.42 * 28 65.83 ±15.68 * 4.96 ± 1.39* 
8 77.00 ± 21.37 3.42 ± 0.97* 29 91.40 ± 12.88 0 
9 53.00 ± 17.58 * 2.12±1.60 * 30 89.40 ± 11.22 0 
10 47.80 ± 18.66 * - 31 26.25 ± 19.92 * - 
11 100.00 ±0 1.83 ±1.13* 32 88.33 ± 16.26 3.82±2.11* 
12 100.00 ±0 2.73 ±1.19* 33 39.83 ±11.90* 0 
13 43.50 ± 11.90 * - 34 52.20 ± 20.00* 3.30 ± 2.71* 
14 61.60 ± 28.95* 3.08 ± 0.78* 35 40.60 ±  16.47* - 
15 96.83 ± 4.99 5.38 ±1.78 36 82.67 ± 15.98 0 
16 84.33 ± 23.35 4.62 ±2.77* 37 75.83±21.70 1.55±0.9* 
17 76.67 ±19.79 1.72± 0.90* 38 48.67 ± 11.53 * 0 
18 67.40 ± 27.29 * 3.10 ± 1.25* 39 60.33± 19.17 *   4.88± 2.89 
19 88.00 ± 14.35 5.02 ±1.36* 40 73.83±  16.20 * 0 
20 54.50 ± 26.40* 2.60 ± 1.54* 41 37.83 ±15.54  * 0 
21 66.50 ± 22.00* 2.98 ± .0.74* 42 37.60 ±10.79 * 3.21 ± 2.04* 
Nicardipine 93.30 ± 7.42 9.13 ±3.83 Nicardipine 93.30 ± 7.42 9.13 ±3.83 
 
a Studies on isolated rat ileum precontracted with barium chloride (4x10-3 M) 
b Studies on rat thoracic artery precontracted with potassium chloride (67mmol/L) 
* p< 0.05, compared with control responses (n=6) 
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Table 2. EC50 values of the synthesized compounds and nicardipine on isolated rat ileum.  
Compound EC50 
1 0.34±0.17x10-7 *               
2 2.66±1.53x10-7                 
7 0.14±0.08x10-7 *               
11 1.32±0.35x10-7                  
12 2.88±1.67x10-7                  
15 4.63±2.98x10-7                 
16 6.22±4.78x10-7                 
19 0.85±0.68x10-7                 
23 0.55±0.33x10-7*               
25 8.12±1.94x10-7                 
28 7.66 ±4.46x10-7                 
29 4.25±2.72x10-7                   
30 2.17±1.46x10-7                   
32    0.90±0.60x10-7                   
36 4.00±1.27x10-6   
39 4.27 ± 1.85x10-7                 
Nicardipine 1.33±0.34x10-7                  
 
* p< 0.05, compared with control responses   
 
 
4. Discussion 
 
In this work a series of condensed 1,4-dihydropyridines were prepared via modified 
Hantzsch reaction. The structure of the compounds were elucidated by IR, 1H-NMR, 13C-
NMR, DEPT, COSY, X-ray analysis and mass spectra and were confirmed by elemental 
analysis. Their calcium channel modulator activities were investigated on isolated rat ileum 
and thoracic aorta.  
In IR spectra, characteristic N-H, C=O (ester), C=O (ketone) and S=O stretching bonds were 
observed. In 1H-NMR, while the protons of the cyclohexanone ring were at 2.10-2.59 ppm as 
multiplet, each proton of tetrahydrothiophene ring was observed at 2.10-3.40 ppm seperately 
and as dublet of dublet of dublets (ddd). The methyl and methine protons on DHP ring were 
seen at 2.21-2.35 ppm and 4.69-5.71 ppm, respectively. The protons, which are on the 
aromatic rings, were seen at 6.69-7.57 ppm. N-H signals were observed at either 5.75-5.94 
ppm or 9.48-9.90 ppm as singlets. In 13C-NMR spectra of the compounds the number of the 
signals fitted exactly the number of carbon atoms. In COSY spectra of Compound 15, it has 
been determined that there is an interaction between the methylene groups of the 
cyclopentanone ring. The mass spectra of the compounds were recorded via electron 
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ionization technique. Molecular ion peak (M+) or M-1 peak due to the aromatisation of the 
DHP ring to the pyridine analogue were seen in the spectra of all compounds. Cleavage of 
the ester groups and phenyl rings from the parent molecule are the further most observed 
fragmentations.  
The structures of the compounds were also confirmed by elemental analysis and the results 
were within ± 0.4% of theoretical values for all compounds.  
The structure of the compound 14 was also confirmed by X-ray analysis [21]. It was founded 
that, 1,4-DHP ring has very shallow boat conformation, whereas the oxocyclopentene ring is 
planar and there is an intermolecular N-H…….O hydrogen bond between the amine group and 
the carbonyl O atom of the oxoyclopentene ring of a neighbouring molecule.  
 
 
Figure 2: X-Ray diagram of compound 14. 
 
On isolated rat ileum strips precontracted with barium chloride (4x10-3 M) compounds 2, 7, 
11, 12 and 15 are more active than the standard compound, nicardipine, at 10-5 M 
concentration. The most potent calcium antagonists are Compound 11 and 12 with 100 % 
inhibition. When the compounds are compared in respect to the fused rings, it has been 
observed that the compounds carrying cyclopentanone ring have higher activities than the 
derivatives bearing tetrahydrothiofen-1,1-dioxide ring. The compounds with methyl, ethyl 
and allyl esters increased the inhibition of the contraction more than the compounds having 
the other ester groups. Although there is not a distinct relationship between calcium 
modulator activity and the substitution of the phenyl ring, it has been determined that the 
most active compounds (11 and 12) bear 2-fluoro-3-chlorophenyl ring.   
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Half maximal effective concentration (EC50) was also calculated for the compounds, which 
have possessed higher inhibition than 80 % on isolated rat ileum. The results indicated that 
most of the compounds, which have lower EC50 value than nicardipine, have again 
cyclopentanone ring.  
Thirty two compounds, which possessed calcium antagonist activity more than 50 % on 
isolated rat ileum, were also investigated on rat thoracic artery precontracted with potassium 
chloride (67 mmol/L). It was determined that compound 1, 15, 16, 19, 25, 28 and 39 are 
relatively active derivatives. The results indicate that 2,3-dichlorophenyl, 2,3-difluorophenyl 
rings; methyl, ethyl and allyl esters enhance the activity possitively. It was observed again 
that the compounds having cyclopentanone ring were more active.  
When the obtained data are analysed, it can be observed that, most of the active compounds 
bear cyclopentanone ring fused to the 1,4-DHP ring and methyl, ethyl and allyl  moieties in 
ester groups. While the compounds have high activities on isolated rat ileum, most of them 
show lower activities on rat thoracic aorta so it has to be emphasized that the synthesized 
compounds have spasmolytic activity rather than vasodilator activity. 
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